



OPEN ACCESS

EDITED BY

Jaya Kumar,
National University of Malaysia, Malaysia

REVIEWED BY

Salvador Sierra,
University of Michigan, United States
Wendy Walwyn,
University of California, Los Angeles,
United States

*CORRESPONDENCE

Jennifer Lynne Whistler,
✉ jlw@ucdavis.edu

RECEIVED 24 May 2024

ACCEPTED 13 September 2024

PUBLISHED 26 September 2024

CITATION

Gooding SW, Felth L, Foxall R, Rosa Z, Ireton K, Sall I, Gipoor J, Gaur A, King M, Dirks N, Whistler CA and Whistler JL (2024) Deletion of arrestin-3 does not reduce drug-seeking behavior in a longitudinal paradigm of oral morphine self-administration. *Front. Pharmacol.* 15:1438037. doi: 10.3389/fphar.2024.1438037

COPYRIGHT

© 2024 Gooding, Felth, Foxall, Rosa, Ireton, Sall, Gipoor, Gaur, King, Dirks, Whistler and Whistler. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Deletion of arrestin-3 does not reduce drug-seeking behavior in a longitudinal paradigm of oral morphine self-administration

Sarah Warren Gooding¹, Lindsey Felth¹, Randi Foxall², Zachary Rosa¹, Kyle Ireton¹, Izabella Sall², Joshua Gipoor¹, Anirudh Gaur¹, Madeline King¹, Noah Dirks¹, Cheryl Allyne Whistler² and Jennifer Lynne Whistler^{1,3*}

¹Center for Neuroscience, University of California–Davis, Davis, CA, United States, ²Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States, ³Department of Physiology and Membrane Biology, UC Davis School of Medicine, Sacramento, CA, United States

Introduction: Opioid drugs are potent analgesics that mimic the endogenous opioid peptides, endorphins and enkephalins, by activating the μ -opioid receptor. Opioid use is limited by side effects, including significant risk of opioid use disorder. Improvement of the effect/side effect profile of opioid medications is a key pursuit of opioid research, yet there is no consensus on how to achieve this goal. One hypothesis is that the degree of arrestin-3 recruitment to the μ -opioid receptor impacts therapeutic utility. However, it is not clear whether increased or decreased interaction of the μ -opioid receptor with arrestin-3 would reduce compulsive drug-seeking.

Methods: We utilized three genotypes of mice with varying abilities to recruit arrestin-3 to the μ -opioid receptor in response to morphine in a novel longitudinal operant self-administration model. We also created a quantitative method to define compulsivity in drug-seeking based on a multi-variate analysis of several operant response variables.

Results: We demonstrate that arrestin-3 knockout and wild type mice have highly variable drug-seeking behavior with few genotype differences. In contrast, in mice where the μ -opioid receptor strongly recruits arrestin-3, drug-seeking behavior is much less varied. We found that mice lacking arrestin-3 were more likely to meet the criteria for compulsivity whereas mice with enhanced arrestin-3 recruitment did not develop a compulsive phenotype.

Conclusion: These experiments show that a lack of arrestin-3 is not protective against the abuse liability of morphine in an operant self-administration context. Our data also suggest that opioids that engage both G protein and arrestin-3, recapitulating the endogenous signaling pattern, will reduce abuse liability.

KEYWORDS

mu opioid receptor, morphine, arrestin, signaling bias, substance use disorder

1 Introduction

Opioids are powerful analgesic drugs that remain essential for the treatment of severe pain. Despite their therapeutic utility, opioid use can precipitate opioid use disorder (OUD). While most individuals who take opioids do not develop an OUD, over 2% of Americans age 12 and older meet the OUD diagnostic criteria (Substance Abuse and Mental Health Services Administration, 2022) driving a major public health crisis, particularly with accidental overdose. Despite significant research efforts and billions of dollars invested, the development of an opioid with reduced abuse liability has been ultimately unsuccessful (Gooding and Whistler, 2023). This lack of success can be attributed in part to an incomplete understanding of how opioid signaling contributes to the physiological and behavioral components of OUD.

Opioid analgesia is primarily mediated by activation of the μ -opioid receptor (MOR), a G protein-coupled receptor (GPCR) (Matthes et al., 1996). Endogenous opioid peptides, endorphins and enkephalins, bind and activate MOR to promote signaling to the $G_{i/o}$ G protein effectors. G protein signaling from these peptide-occupied MORs is then titrated by a cascade of events that includes phosphorylation of the MOR by GPCR kinases (GRKs) (Doll et al., 2011; Just et al., 2013) and recruitment of the arrestin-3 (β -arrestin-2) effector to the phosphorylated receptor (Zhang et al., 1998). Arrestin-3 recruitment not only uncouples MOR from its G protein but also promotes MOR endocytosis (Keith et al., 1998; Koch et al., 2005). Endocytosed MORs are then dephosphorylated and recycled to the plasma membrane where they can bind ligand and initiate another cycle of signal transduction (Lefkowitz et al., 1998; Tanowitz et al., 2008). Activation of the MOR by opioid drugs, including morphine and all its derivatives, promotes G protein signaling like endogenous ligands. However, morphine-activated receptors only weakly engage the GRK and arrestin-3 effectors (Whistler and von Zastrow, 1998; Just et al., 2013; Miess et al., 2018). This is because the morphine-activated MOR is phosphorylated on only one of the four residues (Doll et al., 2011) that are phosphorylated when the receptor is activated by an endogenous opioid. To denote this difference in MOR signaling by peptide or morphine occupied receptors, we refer to endogenous opioid peptides as balanced ligands: those that potently engage both the G protein and arrestin effectors. Small molecule opioid drugs are more biased: they more strongly engage G protein signaling in many cell types.

The impacts of biased and balanced signaling on the effect/side effect profile of opioid analgesics has been interrogated since the original discovery that morphine does not promote significant MOR endocytosis (Keith et al., 1996; Sternini et al., 1996). Decades later, there remains little consensus on the role of arrestin-3 recruitment in opioid side effects because both eliminating arrestin-3 recruitment and enhancing arrestin-3 recruitment reduces some of the side effects of morphine and strengthens its analgesic effects. Mice without the arrestin-3 gene (Arr3-KO) were reported to show increased analgesia (Bohn et al., 1999), reduced tolerance (Bohn et al., 2000), and reduced respiratory depression and constipation (Raehal et al., 2005) in response to morphine compared to wild type (WT) mice. Likewise, knock-in mice where the MOR is replaced by a mutant receptor which cannot be phosphorylated by GRKs (MOR 11S/T-A) are also reported to show improved analgesia and reduced analgesic tolerance but no difference in respiratory depression in


response to morphine (Kliwer et al., 2019). These data would suggest that removing arrestin-3 engagement improves analgesic utility. However, mice with a chimeric MOR that is an improved substrate for GRKs and have enhanced arrestin-3 recruitment (RMOR mice, for recycling MOR) also show enhanced analgesia and reduced analgesic tolerance to morphine (Kim et al., 2008) with no change in respiratory depression (He et al., 2021). In conditioned place preference (CPP) paradigms, both decreasing (Arr3-KO mice) (Bohn et al., 2003) and increasing (RMOR knock-in mice) (Berger and Whistler, 2011) arrestin-3 recruitment increases the potency of morphine reward. Finally, dependence, defined as physical and/or affective signs of distress upon the removal of drug, is another negative side effect of opioid use and a key component of OUDs. Both mouse lines deficient in arrestin-3 recruitment (Arr3-KO, MOR 11S/T-A) show intact or exacerbated morphine withdrawal signs, indicating that they still develop dependence (Bohn et al., 2000; Kliwer et al., 2019). In contrast, RMOR mice show neither physical (Kim et al., 2008) nor affective (Berger and Whistler, 2011) signs of dependence upon withdrawal from morphine. This battery of conflicting results has left the field divided on the best therapeutic strategy for new opioid drugs.

In humans, OUD is a syndrome defined by a constellation of symptoms that include loss of control in drug-seeking behavior, craving, and relapse as well as physiological tolerance and dependence. Although not all aspects of human OUD can be modeled in mice, we have previously reported a three-phase operant self-administration paradigm that models aspects of OUD in mice: escalation of drug-seeking (loss of control), failure to extinguish drug-seeking (craving), and reinstatement after prolonged abstinence (relapse) indicative of compulsive drug seeking. We use the term compulsive as a vernacular tool to describe differences in behavior across all phases of the paradigm, similar to how an OUD in human is diagnosed as a composite of symptoms. Using this model, we demonstrate that some WT but no RMOR mice become compulsive drug-seekers with time (Berger and Whistler, 2011). However, it is not known how eliminating arrestin-3 impacts compulsive drug-seeking behavior in this mouse model. Since many of the side effects of opioids are improved with both the enhancement and the elimination of MOR-arrestin-3 interaction, its impact on drug-seeking is difficult to predict. We utilized a version of our drug-seeking model in three genotypes: WT, Arr3-KO, and RMOR to determine how patterns of drug-seeking overtime were altered by increased and eliminated arrestin-3 activity at the MOR.

2 Materials and methods

2.1 Mice

Mice of three genotypes were used in this study: 1) C57Bl/6 WT ($n = 20$, 14 male, six female, five bred in-house and 15 purchased from the Jackson Laboratory, three females and 12 males were purchased, three females and two males were bred in house) 2) RMOR (Kim et al., 2008) ($n = 15$, eight male, seven female) bred in house, congenic >30 generations on C57Bl/6 and 3) Arr3-KO (Bohn et al., 1999) ($n = 16$, seven male, nine female) originally acquired from Dr. R. Lefkowitz (Duke University) (Bohn et al., 1999) and



bred in-house congenic for >30 generations on C57Bl/6. Adult mice aged 9–11 weeks at the start of training were used. For the physical dependence experiments, a separate group of C57Bl/6 WT mice were used (morphine group: four male, four female; saline group: five male; purchased from the Jackson Laboratory). Mice were singly housed with running wheels as extra enrichment upon entering the study and had access to food and water *ad libitum*. Single housing was necessary to monitor morphine consumption in the home cage. Mice were housed in a room with a reversed 12-hour dark/light cycle so that all study tasks took place during their active/dark period. An independent group of mice (C57Bl/6 WT male mice purchased from

the Jackson Laboratory) was used to determine the oral morphine dose response curve.

2.2 Determination of physical dependence to oral morphine

Mice were given 9 weeks of oral morphine in which *ad libitum* morphine (n = 8, four male, four female), or 0.2% saccharin vehicle (n = 5 male), was available in the home cage in addition to water for 5 days a week and removed for 2 days each week. In the first week,

morphine was provided at 0.5 mg/mL in 0.2% saccharin and increased to 0.75 mg/mL for the following weeks (see Figures 1A, B). Following this exposure schedule, mice were assessed for physical dependence to morphine. Mice were injected subcutaneously with 10 mg/kg morphine followed by a 5 mg/kg naloxone injection 30 min later. They were observed in clear plexiglass chamber for 20 min by a blind observer. Signs of withdrawal including jumping, wet-dog shakes, teeth-chattering, and paw tremors were recorded. A global withdrawal score was calculated as the sum of these behaviors.

2.3 Generation of oral dose-response curve to morphine

A dose-response curve to orally administered morphine was determined using a radiant heat tail-flick assay (Tail-flick Analgesia Meter, Columbus Instruments, Columbus, OH). The light intensity was adjusted such that baseline latency (no drug present) to tail flick was 1.4–2.0 s. A maximum of three times the baseline latency (6.0 s) was used as a cutoff time to prevent tissue damage. For measurement of tail flick response latency, mice were gently restrained using a fabric pouch with their tail placed at the heat source. A foot pedal was used for initiation and quick release of heat synchronized to the built-in timing apparatus. A minimum of five independent subjects were tested for each dosing group. An oral gavage solution in sterile saline was prepared so that each subject received a maximum of 100 μ L when dosed by kilogram. Doses used were 5, 10, 15, 25, and 100 mg/kg. Response latencies of tail flick were measured 45 min following oral gavage of morphine solution. A non-linear fit equation in GraphPad Prism was used to determine the EC₅₀ dose of oral morphine. Data are displayed as Analgesic Maximum Possible Effect:

$$\%MPE = 100 \times \frac{\text{drug response latency} - \text{baseline latency}}{\text{cutoff time} - \text{baseline latency}}$$

2.4 Operant training with saccharin reward

Med Associates operant conditioning chambers (Fairfax, VT) were used for the extent of this study. Mice were first trained to press a lever for a reward using saccharin as the reinforcer. Both active and inactive levers were present at the start of training. The active lever was indicated by the presence of a light cue above the lever while inactive levers were unlit. A press on the light-cued active lever delivered 15 μ L of 0.2% saccharin sodium salt hydrate (Sigma-Aldrich, St. Louis MO) that was signaled by the illumination of a cue light above the delivery port and a 2.5-second tone (see Figure 2A). Mice were trained in two stages: Stage 1 consisted of a progressive fixed ratio (FR) reinforcement schedule from FR1 (every active lever press produces a reward) to FR4 (four consecutive presses are required to produce a reward). Mice progressed to the next FR schedule after they obtained 20 rewards at each FR. To pass Stage 1 mice had to press a total of 200 times for 80 rewards (20 at FR1, 40 at FR2, 60 at FR3, and 80 at FR4). Each session lasted a maximum of 6 h. Mice that failed to pass Stage 1 after six sessions were eliminated from the study. In Stage 2, mice were returned to the box

for an FR1-FR4 progressive session with one reward at each FR step before progressing to the next step: admittance into the study. To pass Stage 2, mice had to press the active lever 10 times for 4 rewards (1 press at FR1, 2 at FR2, 3 at FR3, and 4 at FR4). Only mice that passed Stage 2 within 1 h were entered into the study.

2.5 Oral morphine consumption schedule

Mice who successfully completed saccharin operant training with saccharin were singly housed and their cages were outfitted with two bottles, one with water and the other with morphine sulfate (MS) (Mallinckrodt Pharmaceuticals, St. Louis, MO) + 0.2% saccharin to counteract the bitter taste of MS. Animals were unexposed to morphine prior to this point. In addition, to acclimate mice to the bitter taste of MS, the concentration of MS was 0.3 mg/mL in the first week and 0.5 mg/mL in the second week (Figure 2Aii). After this, the concentration was increased to 0.75 mg/mL for the duration of the home cage drinking period (16–19 weeks). Mice had access to both the MS bottle and the water bottle 5 days per week and water only for the 2 days preceding each weekly operant session. MS and water bottles were weighed three times a week to monitor total morphine consumption. Importantly, neither RMOR mice (Berger and Whistler, 2011) nor Arr3-KO mice (Li et al., 2013) show differences in preference for saccharin compared to WT mice.

2.6 Operant oral self-administration weekly schedule

After saccharin training was completed, morphine naïve mice entered a recurrent weekly schedule for 16–19 weeks (Figure 2Aii). Mice received weekly operant self-administration sessions simultaneously with the home cage drinking schedule described above. After 2 days of access to only water, mice were placed in the operant box for a 30-minute session (peach bars, Figure 2Aii) that consisted of two distinct phases: a timeout period and a reinforcement period. The timeout period was signaled by the presence of a flashing light above the active lever and no light above the inactive lever. No lever presses were rewarded during this 5-minute timeout period, which in our OUD model reflects futile drug-seeking. After the 5-minute timeout, the light above the active lever stopped blinking and remained on, initiating the start of the 25-minute reinforcement period. During this period, the first active lever press was rewarded by delivery of a 15 μ L oral morphine reward (0.5 mg/mL MS in 0.2% saccharin), paired with the illumination of the light above the port and a 2.5-second tone. After that first reward, the wait time necessary between available rewards was unpredictable, from 1 to 90 s, but averaged 25 s. Time intervals for the variable interval reinforcement schedule were randomly selected from a 12-element Fleshler–Hoffman series to ensure all mice could access the same number of rewards (Fleshler and Hoffman, 1962). In our OUD model, a variable interval schedule was chosen to capture rates of lever pressing that reflect how hard a mouse is willing to work for drug since not all presses produce reward. All lever presses and all rewards consumed were automatically recorded during this weekly 30-min session. After








FIGURE 2 Deletion of arrestin-3 does not reduce drug-seeking behavior in an operant self-administration task. **(A)** Experimental paradigm for longitudinal model of OUD. i. Schematic of operant self-administration chamber where lever pressing resulted in delivery or denial of a morphine reward. ii. Experimental timeline. Top bar shows example weeks where slashes indicate a repetition of previous weeks. Middle bar shows oral MS availability in the home cage where blue bars represent water alone and increasing concentrations of morphine (0.3 mg/mL, 0.5 mg/mL, and 0.75 mg/mL morphine) are lightest to darkest purple (middle bar). Mice were able to drink morphine *ad libitum* in their home cage (Figure 1A) for 5 days a week and water 7 days a week during the self-administration phase of the paradigm. Bottom bar shows the three phases of the paradigm. Phase one: 16–19 weeks of home cage drinking, with an operant self-administration session (peach bars) 1 day per week. Phase 2: Lever pressing behavior was extinguished in up to 12 extinction (Continued)

FIGURE 2 (Continued)

sessions (green bars). Phase 3: Cue-induced reinstatement (light purple bar) of lever pressing following a 14-day period of complete morphine abstinence. **(B)** Schematic of MOR signaling in WT (gray), Arr3-KO (orange), and RMOR (teal) mice in response to morphine and the endogenous ligand, endorphin. Effectors include Gi/o/z protein (Gi, circle), Arrestin-3 (Arr3, square) **(C)** Lever pressing behavior during operant self-administration phase in WT (gray), Arr3-KO (orange) and RMOR (teal) mice. Lever press counts are summarized (mean and standard error) for every 3 weeks of the self-administration phase with the distribution of individual subject counts displayed on the alternate weeks. Three types of lever press behaviors are described. Timeout (circles): any lever press that occurs in the first 5 minutes of a 30-min session, Inactive (triangles): a press on an inactive lever during the final 25 min of a session, Active (squares): a press on an active lever during the final 25 min of a session. Only active lever presses could trigger reward delivery. **(D)** Rewards collected during operant self-administration phase. Reward collection counts of WT (black), Arr3-KO (orange), and RMOR (teal) (same colors as above) are summarized (mean and standard error) for every 3 weeks with the distribution of individual subject counts displayed on the alternate weeks. **(E)** Reward rate during operant self-administration phase. Reward rate was calculated as rewards collected/total lever presses for each session. Session reward rates for WT, Arr3-KO, and RMOR (same colors as above) are summarized (mean and standard error) for every 3 weeks with the distribution of individual subject rates displayed on the alternate weeks.

the operant self-administration session, mice were returned to their home cage with *ad libitum* access to both water and morphine for the next 5 days followed by 2 days of water access. This weekly schedule was repeated for 16–19 weeks.

2.7 Extinction

Following 16–19 weeks of weekly operant self-administration, three back-to-back 30-minute extinction sessions (90-minute cumulative time in operant chamber) were conducted every day for a maximum of 12 days (Green bars, Figure 2Aii). Extinction sessions were identical to the self-administration sessions except that lever presses on the active lever never led to a morphine reward or the associated tone and light cues during any part of the session. Each mouse was assigned an individual extinction criterion delineated as an active lever press daily session average below 20% of their weekly session average during the final 3 weeks of their self-administration phase or four or fewer active lever presses, whichever number was higher. Once this criterion was met, the mouse moved on to the next phase of the paradigm (14 days of abstinence). Some mice therefore had more extinction sessions than others and all mice had 14 days of abstinence after extinction. All lever presses during these extinction sessions were automatically recorded. During the extinction phase, mice had access to only water (no morphine) in their home cage.

2.8 Abstinence and reinstatement

Following extinction, mice were returned to their home cage with access to only water for 14 days with no morphine access (light purple bar, Figure 2Aii). Following this abstinence period mice were returned to the operant box for a single 30-minute operant session. This session consisted of a 5-minute timeout period identical to previous sessions. After this timeout period, the light over the active lever remained on and a single non-contingent (no lever press required) morphine reward (15 μ L of 0.5 mg/mL MS in 0.2% saccharin) was delivered at the port with the associated light and sound cues. After this single non-contingent reward delivery, the light remained on over the active lever, but no additional rewards or cues were delivered. During this session, all lever presses, all head port entries, and the latency to collect the non-contingent reward were recorded.

2.9 Calculation of compulsivity composite scores

Principle Coordinate Analysis and correlations analyses conducted in the R software packages factextra (v 1.0.7) and corrplot (v 0.92) were used to identify measured behaviors through the paradigm indicative of drug abuse liability and that distinguish WT and RMOR mice from each other. A total of 16 measures from throughout the paradigm were selected to create a composite OUD/compulsivity score for each mouse (see Figure 4A for the variables used in the final score). The raw values for each mouse for each of these 16 measures were Z scored across the population of mice that completed the study (51 mice: 20 WT, 15 RMOR, 16 Arr3-KO). To give each phase equal weight when calculating the final score, a sub-score for each of the three phases (self-administration, extinction, reinstatement) was then created by averaging the Z scores of each behavioral measure in that phase for each mouse. The values for the operant self-administration phase came from the average of the final three weekly sessions for that mouse. The extinction values represented the average of the three sessions on each animal's first day of extinction. A final compulsivity score was then created by adding the self-administration, extinction, and reinstatement sub-scores for each mouse. The distribution of composite compulsivity scores of WT mice were bimodal (R software package mclust), thus we used the mean and interquartile standard deviation (IQD) of WT compulsivity scores to determine categorical assignments of compulsive or non-compulsive for the entire population. The IQD is defined as the standard deviation of values between Q1 and Q3. All mice with a composite score of 1 IQD or more over the mean score of WT mice were designated as compulsive.

2.10 Morphine preference

On days 3–5 of the final week of the operant self-administration phase, we conducted a preference test for morphine (sweetened with 0.2% saccharin) versus saccharin alone. To do this, the water bottle in the home cage was replaced with a bottle of 0.2% saccharin for 4 h during the dark cycle, and consumption of both morphine and saccharin was determined by weighing the bottles before and after this test. Preference for morphine over saccharin was calculated AS MS consumed (in mLs)/Total fluid consumed (in mLs).

2.11 Statistical analysis

All statistics were conducted using R and the RStudio software except for Figures 1B, D, which were constructed in GraphPad Prism software. Statistical tests were chosen based on the distribution of data in each group. Normality of data was assessed using a Shapiro-Wilk test and data with a p-value greater than 0.05 was considered normal. One-way ANOVA or t-tests were used to compare differences between groups where assumptions for normality and homogeneity of variance were met. The Kruskal–Wallis was used when assumptions of normality were not met.

2.12 Study approval

All protocols were approved by the Institutional Animal Care and Use Committee at the University of California Davis and are in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals.

3 Results

3.1 Oral morphine self-administration is sufficient to produce both analgesia and dependence

To emulate human-like patterns of OUD in a rodent model, we developed a paradigm that allowed mice to engage in naturalistic drug-taking with substantial drug exposure from voluntary home-cage consumption each week, but also yielded sufficient information to quantify motivated drug-seeking behavior. To accomplish this, we utilized a combination of traditional operant self-administration and a variation of the two-bottle choice drinking task similar to a model we have described previously (Berger and Whistler, 2011). To validate that the paradigm provides sufficient drug exposure, we examined whether voluntary drinking on this schedule was sufficient to produce opioid dependence in WT C57Bl/6 mice. Mice consumed between 17.0 and 44.8 mg/kg daily. Following 9 weeks of home cage morphine drinking (Figures 1A, B), we evaluated mice for common effects of opioid withdrawal precipitated by naloxone injection (5 mg/kg). Mice that had access to morphine in their home cage had significantly higher global withdrawal scores than those who had access only to the 0.2% saccharine vehicle solution ($p = 0.0047$, $t = 3.5275$, $df = 11$, two-tailed unpaired t-test) (Figure 1C). In a separate set of mice, we also confirmed that oral gavage of morphine at doses comparable to daily voluntary morphine consumption was sufficient to produce analgesia in a tail flick assay (Figure 1D).

3.2 Deletion of arrestin-3 does not reduce drug-seeking behavior in a longitudinal OUD model

The WT MOR recruits arrestin-3 very weakly in response to morphine activation when compared with the recruitment promoted by endorphins/enkephalins (Finn and Whistler, 2001)


(Figure 2B, gray). Following validation of the voluntary drinking schedule, we entered new mice into our longitudinal mouse model of OUD including two transgenic mouse lines with altered arrestin-3 recruitment to determine whether the degree of arrestin-3 recruitment to the MOR modulates drug-seeking. In Arr3-KO mice, the MORs have no ability to recruit arrestin-3 (Figure 2B, orange). In RMOR mice, the receptor recruits arrestin-3 in response to both endorphin and morphine activation (Figure 2B, teal) (Finn and Whistler, 2001; Kim et al., 2008; Madhavan et al., 2010).

To monitor the transition to compulsive drug-seeking and relapse as described previously (Berger and Whistler, 2011), we implemented a paradigm which consisted of three separate stages: 1) Weekly Operant Self-administration 2) Extinction and 3) Reinstatement (Figure 2Aii). Drug-seeking behavior was evaluated during each phase in an operant task (Figure 2Ai) during which presses on an active lever may or may not yield an oral morphine reward on a variable interval reinforcement schedule. Mice were initially trained to press the lever for a saccharin reward and only mice who met the initial training criteria were advanced to the morphine-seeking task. Only three mice failed to pass the saccharin training stage and were omitted from the study prior to the morphine-seeking phase. No morphine exposure occurred prior to operant training.

Mice in all three genotypes learned the task at equivalent rates and demonstrated a preference for the active lever over futile lever pressing (presses on an inactive lever or on any lever during the initial timeout period of the session). Lever pressing activity was stable through many weeks of self-administration sessions, and there were no significant differences from average WT lever pressing behavior in RMOR or Arr3-KO mice (determined by one-way ANOVA with Tukey's multiple comparisons test) (Figure 2C). On average, RMOR mice achieved fewer morphine rewards during operant sessions (Figure 2D), but this was not statistically significant. When corrected for total lever pressing behavior, their reward rate was not different from the other two groups (Figure 2E).

Following the operant self-administration phase of the paradigm, mice were given extinction sessions three times daily in which cues and drug reward were no longer presented in response to active lever presses. Extinction sessions were ceased once a mouse met an individualized criteria determined as 20% of active lever pressing displayed during late operant sessions, or fewer than four lever presses in a session. Mice that reached 12 days of extinction training were automatically advanced to the next phase of the paradigm. This combination of individual and static extinction criteria were chosen to allow thorough extinction could occur before the reinstatement test while also maintaining that the longitudinal exposure paradigm was reasonably similar across animals. The majority of mice extinguished their drug-seeking behavior within 12 days, but there was a significant effect of genotype on days to reach extinction ($p = 0.036$, $F = 3.566$, $df = 2$, one-way ANOVA) as Arr3-KO mice took longer to reach extinction compared to the WT group ($p = 0.028$, Tukey's multiple comparisons test) (Figure 3A). Seven out of 16 (43.75%) Arr3-KO mice did not reach their behavioral extinction criteria within 12 days, something that only occurred in 2 (13%) RMOR and 1 (5%) WT mouse.

After extinction, all mice returned to their home cage for 2 weeks of abstinence with access to only water to drink. Each mouse



received an identical number of abstinence days beginning the day following their final extinction session. Following this abstinence period mice were returned to the operant box for a single operant reinstatement session. This session was identical to a single 30-min extinction session except mice received a single non-contingent morphine reward at the termination of the timeout period. Genotype significantly affected drug-seeking behavior during reinstatement ($p = 0.02$, $df = 2$, Kruskal-Wallis test) as Arr3-KO

mice displayed more active lever pressing than WT and RMOR groups ($p = 0.035$ and $p = 0.039$ respectively, Dunn test) (Figure 3B). This is likely because several Arr3-KO mice did not effectively extinguish their drug-seeking behavior. A Kruskal-Wallis test did not reveal a significant genotype effect in active lever pressing on the final extinction day ($p = 0.068$), but Arr3-KO mice pressed more than other groups reflecting their lack of extinction. Overall futile lever pressing (inactive lever pressing or lever pressing during the




FIGURE 4 (Continued)

change in median lever press count between the first and median final day of extinction for each group. RMOR mice are not shown as they do not have a subset of compulsive animals. (E) Active lever presses during each paradigm phase in compulsive and non-compulsive mice. Lever pressing summary data from Figure 3B is revisualized with compulsive (red) and non-compulsive (gray) mice summarized (mean and SEM) as distinct groups. RMOR mice are not shown as they do not have a subset of compulsive animals.

timeout period) was significantly affected by genotype ($p < 0.001$, $df = 2$, for both futile lever types, Kruskal–Wallis test). RMOR mice displayed significantly less inactive ($p < 0.001$) and timeout ($p = 0.002$) lever pressing than WT despite no significant difference in their active lever pressing ($p = 0.559$, Dunn test) (Figures 3C, D) demonstrating that our paradigm can demonstrate reduced OUD-like behaviors as is expected of this genotype (Berger and Whistler, 2011). Conversely, Arr3-KO mice had slightly more futile lever pressing behaviors overall ($p = 0.017$ for both futile lever types, Dunn test) compared to WT mice, though this is partially driven by their increased tendency to press the inactive lever early in the self-administration phase. Overall, these data show that while the RMOR phenotype may offer some protection from compulsive drug-seeking behaviors in this model, arrestin-3 deletion does not offer improved outcomes after prolonged morphine exposure and may increase compulsive drug-seeking.

3.3 Arrestin-3 deletion does not improve compulsivity as defined by a behavioral composite score

OUD is a complex diagnosis that involves a combination of behaviors and varies in its individual presentation. Because our experimental paradigm was designed to encapsulate several addiction-relevant behaviors, we considered a multi-variate analysis strategy. A Principal Coordinate Analysis (PCoA) of 16 behavioral measures across our entire operant paradigm (Figure 4A) revealed that RMOR mice clustered tightly, whereas both WT and Arr3-KO mice had high variability across both dimensions (Figure 4B). We posited that this variability could reflect a bifurcation of phenotype in the WT and Arr3-KO groups in which a subset of mice adopt a more addiction-like behavior pattern just as a subset of humans exposed to opioids develop OUD (Lagisettey et al., 2021).


We calculated a composite score for each mouse that incorporated all 16 measures used in the PCoA (Figure 4A). These 16 behavioral measures included lever pressing activity on inactive levers and lever pressing during the timeout period of the session. These measures were included in the composite score as a model of futile drug-seeking behavior, an indicator of more effort expenditure to obtain drug. To facilitate a comparative analysis of low and high scoring mice, we created a quantitative designation to separate the mice into two groups. Mice were designated “compulsive” if their composite score fell above a threshold determined as one interquartile deviation above the mean composite score of the WT group (Figure 4C). By these criteria, of the 20 WT mice, 6 (30%) were compulsive. Of the 16 Arr3-KO mice, 10 (62.5%) were compulsive. None of the 15 RMOR mice were compulsive, replicating what we have previously shown (Berger and Whistler, 2011). Comparison of composite compulsivity scores

showed a significant genotype effect (Figure 4C, $p = 0.001$, $F = 8.007$, $df = 2$, one way ANOVA). In a Tukey’s multiple comparisons test, Arr3-KO mice had no significant difference in compulsivity score from the WT group ($p = 0.262$), but WT and RMOR mice show a significant difference in compulsivity ($p = 0.031$) (Figure 4C). These data confirm our previous work indicating that effective arrestin-3 engagement diminishes the liability for compulsive drug-seeking. Further, they suggest that preventing arrestin-3 engagement does not reduce compulsive drug-seeking and it may even exacerbate it. This is a deviation from what we see with the physiological effects of analgesia and tolerance where both enhancement and elimination of the arrestin-3 pathway cause similar shifts. However, it aligns with the RMOR phenotype of reduced physiological and affective dependence that is absent in Arr3-KO mice.

When we re-visualize the lever pressing behaviors after separating the mice into compulsive and non-compulsive groups, we observe a divergence of activity that is not apparent when we examined genotype differences. When mice are combined across genotypes, compulsive mice take several more days to extinguish their lever-pressing behavior ($p = 0.012$, $df = 1$, Kruskal–Wallis test) (Figure 4D). They also show an apparent escalation in drug-seeking through the self-administration phase that is not echoed by the non-compulsive group. This is apparent in the divergence of active lever pressing which is significantly higher in compulsive mice at the end of the self-administration phase ($p < 0.001$, $df = 1$) despite there being no difference between the same mice at the outset of the phase ($p = 0.337$, $df = 1$, Kruskal–Wallis test) (Figure 4E). This is not surprising, as these variables are contained in or derived from those within the composite scores used to assign the compulsivity threshold. It does, however, affirm the hypothesis that drug-seeking phenotypes may be more appropriately treated as bimodal than just highly variable. This idea is bolstered by the tightly clustered variability of the RMOR mice, none of which were compulsive.

3.4 Compulsive drug-seeking behavior is independent of morphine consumption or preference

The vast majority of the morphine consumption in our paradigm occurred during home cage drinking. Individual mice were highly variable in their weekly morphine consumption with a range of 2.09–11.1 mg consumed per week, on average. There was no significant difference in average morphine consumption ($p = 0.799$, $df = 1$, Kruskal–Wallis test) between WT and Arr3-KO mice (Figure 5A). There was no correlation in total morphine consumption and compulsivity score ($p = 0.57$, $R = -0.097$) (Figure 5B). There was also no significant difference in morphine



consumption between compulsive and non-compulsive mice, (Figure 5C, $p = 0.239$, $df = 1$, Kruskal–Wallis test).

Because individuals with OUD often display a preference for opioid drugs over other sources of positive affect, we also assessed whether drug-seeking behavior was related to voluntary consumption of morphine (a drug reward) over saccharin (a naturalistic reward). During week 17 of our self-administration phase of the paradigm, we measured morphine and saccharin consumption in a traditional two bottle choice test over a four-hour period. Interestingly, morphine solution was not preferred over saccharin vehicle during this test period, despite the fact that the voluntary morphine consumption in this paradigm is sufficient to drive physical dependence (Figure 1C). There was no significant difference in preference for morphine versus saccharin between WT and Arr3-KO mice ($p = 0.156$, $df = 1$, Kruskal–Wallis test) (Figure 5D). Preference for morphine did not correlate with compulsivity score (Figure 5E, $p = 0.61$, $R = -0.087$) and there was no significant difference in morphine preference between compulsive and non-compulsive mice (Figure 5F, $p = 0.911$, $df =$

1, Kruskal–Wallis test). These data indicate that morphine consumption and preference alone are not predictive of liability for compulsive drug-seeking behavior.

4 Discussion

4.1 Arrestin-3-MOR activity does not cause or exacerbate compulsive drug-seeking

Here we use three genotypes of mice with different abilities to recruit arrestin-3 to the MOR to show that deletion of arrestin-3 does not protect against compulsive morphine-seeking in a mouse model of OUD. This model cannot capture all aspects of human OUD, defined by the human DSM-V criteria. For example, we can't model whether opioids are taken in larger amounts than what was intended, or whether there is a persistent desire or unsuccessful attempts to cut down on usage. However, our model does capture changes in how much time and work is spent seeking drug, how

difficult it is to stop drug seeking (a model of craving), and how strongly after prolonged abstinence drug seeking resumes (reinstatement as a model of relapse). Importantly, our model with a combination of *ad libitum* morphine access and contingent (motivated) drug-seeking also gives sufficient exposure to produce both tolerance and dependence to morphine. In this model, Arr3-KO mice displayed as much morphine-seeking behaviors as WT and RMOR mice. In addition to similar performance in the operant self-administration phase of the paradigm, WT and Arr3-KO mice consumed similar amounts of morphine and showed similar preference for morphine over naturalistic reward in non-contingent drug access contexts. When morphine reward was no longer available, Arr3-KO mice were slower to extinguish their drug-seeking behavior than the other groups. In fact, several Arr3-KO mice achieved the maximum number of extinction days and progressed through the paradigm without reaching their activity-based extinction criteria. When we created a composite score to quantify compulsivity based on a multi-variate analysis of several behavioral outcomes, a subset of both WT and Arr3-KO mice were statistically stronger drug-seekers, and we defined them as “compulsive” seekers as a vernacular tool. In contrast, none of the RMOR knock-in mice exhibited drug-seeking behavior that reached the threshold for compulsive drug seekers (Figure 4C).

These data make a clear case that loss of arrestin-3 activity does not protect against the behavioral components of OUD. The Arr3-KO is a global knockout, and these effects could be influenced by the arrestin-3 pathway at any number of receptors other than MOR. Although it is clear that deletion of arrestin-3 does not improve outcomes in an OUD model, it is possible that increasing engagement of the arrestin-3 pathway offers some protection from abuse liability to morphine as we have previously reported (Berger and Whistler, 2011). No RMOR mice were classified as compulsive in this study nor do they develop analgesic tolerance to morphine under conditions where both WT (Kim et al., 2008; He et al., 2021) and Arr3-KO (He et al., 2021) mice do. RMOR mice also do not show either physical (Kim et al., 2008) or affective (Berger and Whistler, 2011) dependence to morphine whereas both Arr3-KO (Bohn et al., 2000) and MOR 11S/T-A (Kliwer et al., 2019) mice show dependence at a similar or even exacerbated level compared to WT. The development of tolerance and dependence presents major limitations to the clinical utility of opioids and are complimentary to the behavioral exemplars of abuse liability in our operant self-administration model. These combined physiological and behavioral phenotypes in the RMOR mice justify a renewed interest in how arrestin-3 signaling might be exploited for opioid development strategies.

4.2 Opioid reward is an insufficient indicator of abuse liability

In our paradigm, which spanned several months, neither morphine consumption nor morphine preference was predictive of compulsive drug-seeking. Motivation to seek drug as measured by self-administration behavior also did not determine compulsive drug-seeking. Our data overall indicate that compulsive drug-seeking is not driven by opioid reward alone. This suggests that

many of the behavioral assays, including simple operant responding, conditioned place preference, and consumption, traditionally used as addiction proxies, may not be predictive of actual liability to misuse drugs. This is consistent with the observation that although morphine reward is enhanced in both RMOR (Berger and Whistler, 2011) and Arr3-KO (Bohn et al., 2003) mice compared to WT mice, RMOR mice do not transition to compulsive drug-seeking (Berger and Whistler, 2011), while a subset of both Arr3-KO and WT mice do. As morphine is rewarding in all three of these genotypes (Bohn et al., 2003; Berger and Whistler, 2011), these data indicate that future opioid drugs should be evaluated beyond their ability to produce reward with a more holistic understanding of abuse liability.

In humans, OUD is evaluated based on a diverse set of diagnostic criteria that encompass physiological, psychological, and social effects of opioid use (DSM-5, 2013). Though it is impossible to recapitulate all these criteria in an animal model, more care could be taken to appreciate the heterogeneity of the disease. There is no singular model that perfectly encapsulates the human OUD presentation. Even within our own model, mice did not develop a preference for morphine over a natural reward (a popular proxy for addiction-like behavior) even though they were dependent on morphine (a key criterion in the DSM-V). We attempted to better model the multi-symptomatic nature of an OUD with a multi-variate method that employs a PCoA and considers behaviors measured in multiple phases of an extended OUD paradigm. This allowed us to categorize animals into compulsivity groups based on a calculation that assigns equal importance to several behaviors that may or may not ultimately be relevant to the individual. Many models of substance use and misuse are well-established in the field, all of which have a role in unraveling the mechanisms of substance use disorders. Given the complexity of these disorders, it is in the interest of the field to adopt analytical approaches capable of simultaneously considering multiple animal behavioral outputs and how they may interact. We give one example here, but other techniques such as machine learning or meta-analyses would also be useful in evaluating these complex phenotypes.

4.3 Balanced agonism is an under-studied strategy with potential to improve opioid therapeutics

The differentiating characteristic of RMOR mice is that MOR signaling has been altered to reflect that of the endogenous opioids, as the MOR recruits arrestin-3 and is endocytosed and recycled in response to morphine (Madhavan et al., 2010). This is not the case with the WT MOR which only recruits arrestin-3 when GRKs or arrestins are overexpressed (Whistler and von Zastrow, 1998; Zhang et al., 1998). In neurons, opioid peptides, but not morphine, promote MOR endocytosis (Sternini et al., 1996; Arttamangkul et al., 2008), a consequence of arrestin recruitment. Likewise, *in vivo*, morphine administration also produces little endocytosis (He and Whistler, 2005; Madhavan et al., 2010) compared to opioid peptides (He et al., 2002; Trafton and Basbaum, 2004; He and Whistler, 2011). Our data from RMOR and Arr3-KO mice imply that G protein-biased opioid ligands which do not engage arrestin-3 will not prevent abuse

liability. This is a critical finding as opioid drug development has focused on the development of ultra-G-biased ligands for the past 2 decades. TRV-130 (Oliceridine) is one of these ligands and was FDA-approved in 2020—the first new chemical entity opioid in 4 decades. This push to develop ultra-G-biased ligands followed reports that Arr3-KO mice show increased analgesia (Bohn et al., 1999) and reduced tolerance (Bohn et al., 2000) and respiratory depression (Raehal et al., 2005) in response to morphine compared to WT mice, indicating that biased ligands could ameliorate these key side effects. However, several recent reports have failed to reproduce these findings in Arr3-KO mice (Kliwer et al., 2020; He et al., 2021) and clinically, Oliceridine did not significantly reduce respiratory depression (Dahan et al., 2020). As no studies have assessed the abuse liability of the new ultra-biased ligands beyond assessing self-administration (reward) (Austin Zamarripa et al., 2018; Schwienteck et al., 2019; Ding et al., 2020), our results indicate clinically relevant risks that should not be ignored. These findings, coupled with the recent reports on respiratory depression, indicate that ultra G-biased ligands are unlikely to improve on existing side effect risks. For all these reasons, we posit that more work is needed to assess the benefits of a signaling profile that resembles endogenous opioids (Gooding and Whistler, 2023).

We describe endogenous opioid signaling as balanced because it effectively engages both the G protein and arrestin-3 pathways. Recapitulating balanced signaling with exogenous ligands is immensely challenging. Categorizing ligands as balanced or biased depends on quantification of arrestin-3 recruitment and signaling to $G_{i/o/z}$ G protein effectors, techniques which are highly disputed and rife with caveats. This has made it difficult to assign a single signaling bias value for morphine—though it is always more G-biased than the endogenous ligands regardless of GRK/arrestin levels (Gillis et al., 2020; Kolb et al., 2022; Kelly et al., 2023).

The only clinically-utilized opioid drug that approaches a signaling balance comparable to endorphins and enkephalins is methadone (He and Whistler, 2005). No other existing balanced tool compounds have been tested *in vivo* because they have low potency (Johnson et al., 2017), poor solubility (Tidgewell et al., 2008), or were abandoned in favor of ultra G-biased ligands. In preclinical models, methadone produces less tolerance and less dependence than morphine (He and Whistler, 2005). Though it is rarely used as a first line analgesic in humans because of its highly variable half-life, a few controlled studies show reduced tolerance to methadone in humans (Mercadante and Bruera, 2018). However, methadone differs from morphine not only in pharmacokinetics but in many aspects of pharmacology (Ferrari et al., 2004). This makes it difficult to say that bias is the primary factor in its reduced side-effect profile. It would be informative to examine methadone tolerance, dependence, and compulsive drug-seeking in a mouse model that cannot recruit arrestin-3 to the MOR, such as the MOR 11S/T-A knock-in mouse (Kliwer et al., 2019). This effective conversion of methadone into a biased agonist would complement the findings from the RMOR mouse where morphine performs as a balanced agonist.

The phenomenon of the opioid epidemic demands multiple angles of attack. The phenotype of the RMOR mice gives hope that opioid agonists which provide both analgesia and reward without precipitating OUD could still be attainable. This goal remains vital as no alternative drugs exist for the treatment of severe pain. It is past time to expand our strategies in the areas of pharmacology and drug

development and to meet this challenge with a tenacity that rivals that of this public health crisis.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was approved by the University of California IACUC. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

SG: Data curation, Formal Analysis, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing—original draft, Writing—review and editing. LF: Data curation, Formal Analysis, Investigation, Project administration, Supervision, Visualization, Writing—review and editing. RF: Data curation, Formal Analysis, Methodology, Software, Validation, Writing—review and editing. ZR: Data curation, Investigation, Methodology, Writing—review and editing. KI: Formal Analysis, Writing—review and editing. IS: Data curation, Formal Analysis, Visualization, Writing—review and editing. JG: Investigation, Writing—review and editing. AG: Investigation, Writing—review and editing. MK: Investigation, Writing—review and editing. ND: Investigation, Writing—review and editing. CW: Data curation, Funding acquisition, Methodology, Resources, Supervision, Writing—review and editing. Software. JW: Data curation, Funding acquisition, Methodology, Resources, Supervision, Writing—review and editing, Conceptualization, Formal Analysis, Investigation, Project administration, Visualization, Writing—original draft.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was funded by the National Institutes of Drug Abuse under award numbers F31DA056222 (LF) and R21DA049565 (JW, CW), R01DA055708 (JW), F31DA051116 (SG), and by funds provided by the state of California as start up to JW.

Acknowledgments

The authors would like to thank Dr. Robert Lefkowitz for the arrestin-3 knock out mice and all members of the J. Whistler and C. Whistler labs for their valuable input on the manuscript and their ongoing support. We would also like to thank Dr. Rishidev Chaudhuri for his thoughtful evaluation of our manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer WW declared a shared parent affiliation with the author(s) SG, LF, ZR, KI, JG, AG, MK, ND, JW to the handling editor at the time of review.

References

- Arttamangkul, S., Quillinan, N., Low, M. J., Von Zastrow, M., Pintar, J., and Williams, J. T. (2008). Differential activation and trafficking of micro-opioid receptors in brain slices. *Mol. Pharmacol.* 74, 972–979. doi:10.1124/mol.108.048512
- Austin Zamarripa, C., Edwards, S. R., Qureshi, H. N., Yi, J. N., Blough, B. E., and Freeman, K. B. (2018). The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. *Drug Alcohol Depend.* 192, 158–162. doi:10.1016/j.drugalcdep.2018.08.002
- Berger, A. C., and Whistler, J. L. (2011). Morphine-induced mu opioid receptor trafficking enhances reward yet prevents compulsive drug use. *EMBO Mol. Med.* 3, 385–397. doi:10.1002/emmm.201100144
- Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J., and Caron, M. G. (2000). Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature* 408, 720–723. doi:10.1038/35047086
- Bohn, L. M., Gainetdinov, R. R., Sotnikova, T. D., Medvedev, I. O., Lefkowitz, R. J., Dykstra, L. A., et al. (2003). Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. *J. Neurosci.* 23, 10265–10273. doi:10.1523/JNEUROSCI.23-32-10265.2003
- Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., and Lin, F. T. (1999). Enhanced morphine analgesia in mice lacking beta-arrestin 2. *Science* 286, 2495–2498. doi:10.1126/science.286.5449.2495
- Dahan, A., Van Dam, C. J., Niesters, M., Van Velzen, M., Fossler, M. J., Demitrack, M. A., et al. (2020). Benefit and risk evaluation of biased mu-receptor agonist oliceridine versus morphine. *Anesthesiology* 133, 559–568. doi:10.1097/ALN.0000000000003441
- Ding, H., Kiguchi, N., Perrey, D. A., Nguyen, T., Czoty, P. W., Hsu, F. C., et al. (2020). Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. *Br. J. Anaesth.* 125, 596–604. doi:10.1016/j.bja.2020.06.057
- Doll, C., Konietzko, J., Poll, F., Koch, T., Holtt, V., and Schulz, S. (2011). Agonist-selective patterns of mu-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. *Br. J. Pharmacol.* 164, 298–307. doi:10.1111/j.1476-5381.2011.01382.x
- DSM-5 (2013). *Diagnostic and statistical manual of mental disorders: DSM-5™*. Washington, DC: American Psychiatric Publishing, a division of American Psychiatric Association.
- Ferrari, A., Coccia, C. P., Bertolini, A., and Sternieri, E. (2004). Methadone--metabolism, pharmacokinetics and interactions. *Pharmacol. Res.* 50, 551–559. doi:10.1016/j.phrs.2004.05.002
- Finn, A. K., and Whistler, J. L. (2001). Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. *Neuron* 32, 829–839. doi:10.1016/s0896-6273(01)00517-7
- Fleshler, M., and Hoffman, H. S. (1962). A progression for generating variable-interval schedules. *J. Exp. Anal. Behav.* 5, 529–530. doi:10.1901/jeab.1962.5-529
- Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., et al. (2020). Critical assessment of G protein-biased agonism at the mu-opioid receptor. *Trends Pharmacol. Sci.* 41, 947–959. doi:10.1016/j.tips.2020.09.009
- Gooding, S. W., and Whistler, J. L. (2023). A balancing act: learning from the past to build a future-focused opioid strategy. *Annu. Rev. Physiol.* 86, 1–25. doi:10.1146/annurev-physiol-042022-015914
- He, L., Fong, J., Von Zastrow, M., and Whistler, J. L. (2002). Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. *Cell* 108, 271–282. doi:10.1016/s0092-8674(02)00613-x
- He, L., Gooding, S. W., Lewis, E., Felth, L. C., Gaur, A., and Whistler, J. L. (2021). Pharmacological and genetic manipulations at the mu-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice. *Neuropsychopharmacology* 46, 2241–2249. doi:10.1038/s41386-021-01054-x
- He, L., and Whistler, J. L. (2005). An opiate cocktail that reduces morphine tolerance and dependence. *Curr. Biol.* 15, 1028–1033. doi:10.1016/j.cub.2005.04.052
- He, L., and Whistler, J. L. (2011). Chronic ethanol consumption in rats produces opioid antinociceptive tolerance through inhibition of mu opioid receptor endocytosis. *PLoS One* 6, e19372. doi:10.1371/journal.pone.0019372
- Johnson, T. A., Milan-Lobo, L., Che, T., Ferwerda, M., Lambu, E., McIntosh, N. L., et al. (2017). Identification of the first marine-derived opioid receptor “balanced” agonist with a signaling profile that resembles the endorphins. *ACS Chem. Neurosci.* 8, 473–485. doi:10.1021/acscchemneuro.6b00167
- Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., et al. (2013). Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. *Mol. Pharmacol.* 83, 633–639. doi:10.1124/mol.112.082875
- Keith, D. E., Anton, B., Murray, S. R., Zaki, P. A., Chu, P. C., Lissin, D. V., et al. (1998). Morphine activates opioid receptors without causing their rapid internalization: a conserved endocytic Mechanism *In vitro* and in the mammalian brain. *Mol. Pharmacol.* 53, 377–384. doi:10.1124/mol.53.3.377
- Keith, D. E., Murray, S. R., Zaki, P. A., Chu, P. C., Lissin, D. V., Kang, L., et al. (1996). Morphine activates opioid receptors without causing their rapid internalization. *J. Biol. Chem.* 271, 19021–19024. doi:10.1074/jbc.271.32.19021
- Kelly, E., Conibear, A., and Henderson, G. (2023). Biased agonism: lessons from studies of opioid receptor agonists. *Annu. Rev. Pharmacol. Toxicol.* 63, 491–515. doi:10.1146/annurev-pharmtox-052120-091058
- Kim, J. A., Bartlett, S., He, L., Nielsen, C. K., Chang, A. M., Kharazia, V., et al. (2008). Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence. *Curr. Biol.* 18, 129–135. doi:10.1016/j.cub.2007.12.057
- Kliewer, A., Gillis, A., Hill, R., Schmiedel, F., Bailey, C., Kelly, E., et al. (2020). Morphine-induced respiratory depression is independent of beta-arrestin2 signalling. *Br. J. Pharmacol.* 177, 2923–2931. doi:10.1111/bph.15004
- Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., et al. (2019). Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. *Nat. Commun.* 10, 367. doi:10.1038/s41467-018-08162-1
- Koch, T., Widera, A., Bartsch, K., Schulz, S., Brandenburg, L. O., Wundrack, N., et al. (2005). Receptor endocytosis counteracts the development of opioid tolerance. *Mol. Pharmacol.* 67, 280–287. doi:10.1124/mol.104.004994
- Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., et al. (2022). Community guidelines for GPCR ligand bias: IUPHAR review 32. *Br. J. Pharmacol.* 179, 3651–3674. doi:10.1111/bph.15811
- Lagisetty, P., Garpestad, C., Larkin, A., Macleod, C., Antoku, D., Slat, S., et al. (2021). Identifying individuals with opioid use disorder: validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. *Drug Alcohol Depend.* 221, 108583. doi:10.1016/j.drugalcdep.2021.108583
- Lefkowitz, R. J., Pitcher, J., Krueger, K., and Daaka, Y. (1998). Mechanisms of beta-adrenergic receptor desensitization and resensitization. *Adv. Pharmacol.* 42, 416–420. doi:10.1016/s1054-3589(08)60777-2
- Li, H., Tao, Y., Ma, L., Liu, X., and Ma, L. (2013). beta-Arrestin-2 inhibits preference for alcohol in mice and suppresses Akt signaling in the dorsal striatum. *Neurosci. Bull.* 29, 531–540. doi:10.1007/s12264-013-1350-y
- Madhavan, A., He, L., Stuber, G. D., Bonci, A., and Whistler, J. L. (2010). micro-Opioid receptor endocytosis prevents adaptations in ventral tegmental area GABA transmission induced during naloxone-precipitated morphine withdrawal. *J. Neurosci.* 30, 3276–3286. doi:10.1523/JNEUROSCI.4634-09.2010
- Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 383, 819–823. doi:10.1038/383819a0
- Mercadante, S., and Bruera, E. (2018). Methadone as a first-line opioid in cancer pain management: a systematic review. *J. Pain Symptom Manage* 55, 998–1003. doi:10.1016/j.jpainsymman.2017.10.017
- Miess, E., Gondin, A. B., Yousuf, A., Steinborn, R., Mosslein, N., Yang, Y., et al. (2018). Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid mu-opioid receptor desensitization. *Sci. Signal* 11, eaas9609. doi:10.1126/scisignal.aas9609
- Rachal, K. M., Walker, J. K., and Bohn, L. M. (2005). Morphine side effects in beta-arrestin 2 knockout mice. *J. Pharmacol. Exp. Ther.* 314, 1195–1201. doi:10.1124/jpet.105.087254

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

- Schwientek, K. L., Faunce, K. E., Rice, K. C., Obeng, S., Zhang, Y., Blough, B. E., et al. (2019). Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. *Neuropharmacology* 150, 200–209. doi:10.1016/j.neuropharm.2019.01.020
- Sternini, C., Spann, M., Anton, B., Keith, D. E., Jr., Bunnett, N. W., Von Zastrow, M., et al. (1996). Agonist-selective endocytosis of mu opioid receptor by neurons *in vivo*. *Proc. Natl. Acad. Sci. U. S. A.* 93, 9241–9246. doi:10.1073/pnas.93.17.9241
- Substance Abuse and Mental Health Services Administration (2022). Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health.
- Tanowitz, M., Hislop, J. N., and Von Zastrow, M. (2008). Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors. *J. Biol. Chem.* 283, 35614–35621. doi:10.1074/jbc.M806588200
- Tidgewell, K., Groer, C. E., Harding, W. W., Lozama, A., Schmidt, M., Marquam, A., et al. (2008). Herkinorin analogues with differential beta-arrestin-2 interactions. *J. Med. Chem.* 51, 2421–2431. doi:10.1021/jm701162g
- Trafton, J. A., and Basbaum, A. I. (2004). [d-Ala²,N-MePhe⁴,Gly-ol⁵]enkephalin-induced internalization of the micro opioid receptor in the spinal cord of morphine tolerant rats. *Neuroscience* 125, 541–543. doi:10.1016/j.neuroscience.2004.02.019
- Whistler, J. L., and Von Zastrow, M. (1998). Morphine-activated opioid receptors elude desensitization by beta-arrestin. *Proc. Natl. Acad. Sci. U. S. A.* 95, 9914–9919. doi:10.1073/pnas.95.17.9914
- Zhang, J., Ferguson, S. S., Barak, L. S., Bodduluri, S. R., Laporte, S. A., Law, P. Y., et al. (1998). Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. *Proc. Natl. Acad. Sci. U. S. A.* 95, 7157–7162. doi:10.1073/pnas.95.12.7157